As of May 28
| +0.22 / +0.67%|
The 2 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 50.75, with a high estimate of 56.00 and a low estimate of 45.50. The median estimate represents a +53.46% increase from the last price of 33.07.
The current consensus among 2 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.